[
  {
    "id": 1,
    "name": "FMD Vaccine (Trivalent)",
    "type": "Viral Vaccine",
    "marketDemand": 95,
    "profitMargin": 78,
    "technicalFeasibility": 85,
    "competitivePosition": 72,
    "regulatoryComplexity": 65,
    "estimatedInvestment": "1.8-2.4M",
    "currentProduction": "2.5M doses/year",
    "potentialProduction": "8M doses/year"
  },
  {
    "id": 2,
    "name": "PPR Vaccine",
    "type": "Viral Vaccine",
    "marketDemand": 88,
    "profitMargin": 82,
    "technicalFeasibility": 90,
    "competitivePosition": 85,
    "regulatoryComplexity": 55,
    "estimatedInvestment": "1.5-2.0M",
    "currentProduction": "3M doses/year",
    "potentialProduction": "10M doses/year"
  },
  {
    "id": 3,
    "name": "Newcastle Disease Vaccine",
    "type": "Viral Vaccine",
    "marketDemand": 92,
    "profitMargin": 75,
    "technicalFeasibility": 95,
    "competitivePosition": 68,
    "regulatoryComplexity": 45,
    "estimatedInvestment": "1.2-1.8M",
    "currentProduction": "5M doses/year",
    "potentialProduction": "15M doses/year"
  },
  {
    "id": 4,
    "name": "Lumpy Skin Disease Vaccine",
    "type": "Viral Vaccine",
    "marketDemand": 85,
    "profitMargin": 88,
    "technicalFeasibility": 82,
    "competitivePosition": 90,
    "regulatoryComplexity": 60,
    "estimatedInvestment": "1.6-2.2M",
    "currentProduction": "1.5M doses/year",
    "potentialProduction": "6M doses/year"
  },
  {
    "id": 5,
    "name": "Rabies Vaccine",
    "type": "Viral Vaccine",
    "marketDemand": 78,
    "profitMargin": 85,
    "technicalFeasibility": 75,
    "competitivePosition": 65,
    "regulatoryComplexity": 75,
    "estimatedInvestment": "2.0-2.6M",
    "currentProduction": "800K doses/year",
    "potentialProduction": "3M doses/year"
  },
  {
    "id": 6,
    "name": "Anthrax Vaccine",
    "type": "Bacterial Vaccine",
    "marketDemand": 72,
    "profitMargin": 70,
    "technicalFeasibility": 88,
    "competitivePosition": 75,
    "regulatoryComplexity": 50,
    "estimatedInvestment": "1.0-1.5M",
    "currentProduction": "2M doses/year",
    "potentialProduction": "5M doses/year"
  },
  {
    "id": 7,
    "name": "Blackleg Vaccine",
    "type": "Bacterial Vaccine",
    "marketDemand": 68,
    "profitMargin": 65,
    "technicalFeasibility": 92,
    "competitivePosition": 70,
    "regulatoryComplexity": 40,
    "estimatedInvestment": "0.8-1.3M",
    "currentProduction": "1.8M doses/year",
    "potentialProduction": "4M doses/year"
  },
  {
    "id": 8,
    "name": "CBPP Vaccine",
    "type": "Bacterial Vaccine",
    "marketDemand": 80,
    "profitMargin": 72,
    "technicalFeasibility": 80,
    "competitivePosition": 78,
    "regulatoryComplexity": 58,
    "estimatedInvestment": "1.4-1.9M",
    "currentProduction": "1.2M doses/year",
    "potentialProduction": "4.5M doses/year"
  },
  {
    "id": 9,
    "name": "Brucellosis Vaccine",
    "type": "Bacterial Vaccine",
    "marketDemand": 75,
    "profitMargin": 68,
    "technicalFeasibility": 85,
    "competitivePosition": 72,
    "regulatoryComplexity": 62,
    "estimatedInvestment": "1.3-1.8M",
    "currentProduction": "900K doses/year",
    "potentialProduction": "3.5M doses/year"
  },
  {
    "id": 10,
    "name": "Broad Spectrum Antibiotics",
    "type": "Pharmaceutical",
    "marketDemand": 90,
    "profitMargin": 82,
    "technicalFeasibility": 78,
    "competitivePosition": 62,
    "regulatoryComplexity": 70,
    "estimatedInvestment": "2.2-3.0M",
    "currentProduction": "500K units/year",
    "potentialProduction": "2M units/year"
  },
  {
    "id": 11,
    "name": "Anti-helminthic Drugs",
    "type": "Pharmaceutical",
    "marketDemand": 87,
    "profitMargin": 78,
    "technicalFeasibility": 82,
    "competitivePosition": 68,
    "regulatoryComplexity": 65,
    "estimatedInvestment": "1.8-2.5M",
    "currentProduction": "600K units/year",
    "potentialProduction": "2.5M units/year"
  },
  {
    "id": 12,
    "name": "Vitamin Premixes",
    "type": "Pharmaceutical",
    "marketDemand": 82,
    "profitMargin": 65,
    "technicalFeasibility": 90,
    "competitivePosition": 60,
    "regulatoryComplexity": 35,
    "estimatedInvestment": "1.2-1.7M",
    "currentProduction": "1M units/year",
    "potentialProduction": "3.5M units/year"
  }
]
